Cargando…
Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials
The potential of gossypol and of its R-(−)-enantiomer (R-(−)-gossypol acetic acid, AT-101), has been evaluated for treatment of cancer as an independent agent and in combination with standard chemo-radiation-therapies, respectively. This review assesses the evidence for safety and clinical effective...
Autores principales: | Renner, Olga, Mayer, Mascha, Leischner, Christian, Burkard, Markus, Berger, Alexander, Lauer, Ulrich M., Venturelli, Sascha, Bischoff, Stephan C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879263/ https://www.ncbi.nlm.nih.gov/pubmed/35215257 http://dx.doi.org/10.3390/ph15020144 |
Ejemplares similares
-
Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
por: Mayer, Mascha, et al.
Publicado: (2022) -
Epigenetic activities of flavonoids in the prevention and treatment of cancer
por: Busch, Christian, et al.
Publicado: (2015) -
Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2013) -
Correction: Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2013) -
Minerals and Cancer: Overview of the Possible Diagnostic Value
por: Venturelli, Sascha, et al.
Publicado: (2022)